In-depth: What the approval of flucytosine means for the treatment of cryptococcal meningitis in SA

After seemingly endless delays, a critically important drug for the treatment of cryptococcal meningitis was recently approved in South Africa. Yet, while the approval of flucytosine was a major step forward, much more still needs to be done to ensure wide availability of this life-saving medicine for the second leading killer of people living with HIV. Catherine Tomlinson unpacks the details.

Read More

What should the TB priorities be in the new NSP?

The period covered by South Africa’s National Strategic Plan (NSP) for HIV, TB, and STIs 2017 – 2022 will soon come to an end. Against the backdrop of another World TB Day, Tiyese Jeranji asked several local tuberculosis experts what they think the TB priorities should be as South Africa develops an NSP for the next five years.

Read More

PROFILE: I view the doctor-patient relationship as sacred, says leading TB doctor

Dr Jennifer Furin has fought drug-resistant tuberculosis (TB) since 1995, when she worked as a student in a poverty-stricken suburb in Lima, Peru. Since then she has roamed the world, treating TB and HIV patients in under-resourced countries, including Haiti, Russia, Tajikistan, Bangladesh, eSwatini, Lesotho, and South Africa. Biénne Huisman chatted to Furin about her life working in TB and what it means to see things from the perspective of people living with TB.

Read More

Opinion: Health needed a recovery budget, we got the opposite

For healthcare, a post-pandemic human rights-focused budget would have allocated funding specifically for backlogs in access to health services from the past two years, as well as tackling the present inequities in access to healthcare that characterise the public health system. Tshidi Lencoasa, Khanyisa Mapipa, and Julia Chaskalson argue that this year’s budget does not do enough to enable government to realise people’s fundamental human right to access healthcare.

Read More

Study suggests potential role for bnAbs in treating kids living with HIV

Broadly neutralising antibodies (bnAbs) are one of the most active and exciting areas in HIV research. Last year Spotlight reported on a “proof of concept” study showing that a specific bnAb can successfully prevent infection with certain strains of HIV. Now, we also have intriguing findings suggesting that bnAbs may have a role to play in the treatment of HIV in children. Elri Voigt reports.

Read More